INTRODUCTION
C holangiocarcinoma (CCA) is the second most frequent primary malignant neoplasm in the liver and accounts for about 3% of all gastrointestinal cancers 1 . It originates from the epithelium of intra or extrahepatic bile ducts 2 . It has been described by Durand-Fardel for the first time in 1840, and can be divided according to its location into intrahepatic, perihilar (Klatskin tumor) and distal 3 . Histologically, it is usually an adenocarcinoma and displays varying degrees of differentiation and phenotypes 4 . Some risk factors for cholangiocarcinoma have already been established, such as parasitic infections, primary sclerosing cholangitis, bile duct cysts, hepatolithiasis, and some toxins. Other potential risk factors include inflammatory bowel disease, hepatitis B and C virus, liver cirrhosis, diabetes mellitus, obesity, alcoholism, smoking, and genetic mutations 5 . The incidence of CCA has been increasing in recent years 6 .
More attention has been devoted to CCA due to poor prognosis, coupled with the poor efficacy of therapeutic modalities, especially for patients with advanced disease 7 . Chemotherapy has been widely used, though with a low response rate 7, 8 . Staging, size and degree of tumor differentiation, resection margins, and perineural and angiolymphatic invasion are described as prognostic factors 9 . Among the factors that contribute to poor prognosis, the advanced stage of the disease is highlighted, which decreases the chance of cure by surgical treatment 10 . 11, 16 . The overexpression of EGFR in tumor cells was associated with a worse prognosis in some studies, being found in up to 80% of the cholangiocarcinomas, making this receptor a potential therapeutic target in patients with this type of neoplasia [16] [17] [18] [19] . 
RESULTS
There was no significant difference in the proportion between men (n=17) and women (n=18).
The mean patients' age was 58 years, ranging from 28 to 83. There were lower proportions of smokers, alcohol users and gallstones ( Table 1) .
The following procedures with curative intent were performed in 30 patients: eight (26.66%) right hepatectomies, two (6.66%) right trisegmentectomies and nine (30%) left hepatectomies, associated with resection of segment one, four (13.33%) bisegmentectomies (three including segments two and three and one including segments six and seven). The clinical characteristics of patients who had the greatest association with positive expression were female (p=0.06) and absence of comorbidities (p=0.07).
Regarding TNM staging, those with the more advanced stages III and IV had greater EGFR expression (p=0.071). Figure 1 shows the intensities and scores attributed to the cholangiocarcinomas. (Figure 2 ). The expression of EGFR in CCA in previous studies occurred with a variability of 8.1% to 81%, and has been associated with tumors' greater aggressiveness [16] [17] [18] [19] .
Figure 1. Intensity of EGFR in cholangiocarcinomas. HE staining on the left (a, c, e, g) and EGFR immunohistochemistry on the right (b, d, f, h). (b)
In our study, EGFR expression was considered positive in 28.6% of the cases and, although there was no statistical significance, we found a higher rate of expression in tumors in advanced stages, occurring in 42.1% of stages III/IV versus 12.5% of stages I/II (p=0.071), translating characteristics of aggressive phenotype in the presence of invasive disease. One hypothesis is that the tumor will express more EGFR upon reaching advanced stages.
Survival analysis also corroborated the hypothesis that EGFR expression is associated with a worse prognosis, since patients considered positive had lower survival rates than negative ones. 
